BCP
BMRN icon

Blackhawk Capital Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Blackhawk Capital Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,545
Closed -$146K – 100
2018
Q2 		$146K Sell
1,545
-5
-0.3% -$438 0.17% 101
2018
Q1 		$126K Sell
1,550
-130
-8% -$11.2K 0.11% 122
2017
Q4 		$150K Buy
+1,680
New +$146K 0.13% 103

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blackhawk Capital Partners's BMRN Position: Q3 2018 in Review

Blackhawk Capital Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2018, closing a stake of 1,545 shares — an estimated $146K sold.

Blackhawk Capital Partners first reported a position in BMRN in Q4 2017 and held it in 3 quarters. The position peaked at $150K in Q4 2017. 459 funds tracked by Wall St. Rank hold BMRN as of Q3 2018.

  • Blackhawk Capital Partners reported no remaining BioMarin Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Blackhawk Capital Partners sold 1,545 BioMarin Pharmaceuticals shares in Q3 2018, an estimated $146K.
  • Blackhawk Capital Partners first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • Blackhawk Capital Partners's BioMarin Pharmaceuticals position peaked at $150K in Q4 2017.
  • 459 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2018.

Based on Blackhawk Capital Partners's 13F filing for Q3 2018, filed 13 Nov 2018.